Cargando…

Effect of Roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study

BACKGROUND: Renal anemia of diabetic kidney disease (DKD) shows higher incidence rate, earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, improves CKD anemia. This retrospective cohort study evaluates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, Liu, Yulu, Huang, Ying, Zhao, Yuee, Wei, Cong, Yang, Kexin, Li, Xiaohui, Zhang, Shumin, Wang, Wenpeng, Liu, Yu, Liu, Fuyou, Sun, Lin, Xiao, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761136/ https://www.ncbi.nlm.nih.gov/pubmed/36544686 http://dx.doi.org/10.21037/atm-22-4344

Ejemplares similares

Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011)

Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia
por: You, Xiaoe, et al.
Publicado: (2022)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia
por: Landau, Daniel, et al.
Publicado: (2018)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis
por: Vočanec, Danijela, et al.
Publicado: (2018)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
por: Zheng, Xiaomeng, et al.
Publicado: (2023)

Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis
por: Zhang, Li, et al.
Publicado: (2021)

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
por: Zhang, Huifang, et al.
Publicado: (2020)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

PB2482: ROXADUSTAT SUPPRESSES ADIPOGENESIS IN HUMAN BMMSC AND PROMOTES EPO PRODUCTION VIA REGULATION OF HIF SIGNALING PATHWAYS
por: Zhang, Jing, et al.
Publicado: (2023)

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1(+) Cells
por: Jatho, Aline, et al.
Publicado: (2022)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study
por: Trincavelli, Maria Letizia, et al.
Publicado: (2013)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin
por: Yang, Xiaowei, et al.
Publicado: (2021)

Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia
por: Xu, Bojun, et al.
Publicado: (2021)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease
por: Zhang, Yanjing, et al.
Publicado: (2023)

Comparison of Neurite Outgrowth Induced by Erythropoietin (EPO) and Carbamylated Erythropoietin (CEPO) in Hippocampal Neural Progenitor Cells
por: Oh, Dong Hoon, et al.
Publicado: (2012)

EPO does not promote interaction between the erythropoietin and beta-common receptors
por: Cheung Tung Shing, Karen S., et al.
Publicado: (2018)

Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
por: Soliz, Jorge, et al.
Publicado: (2020)

Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients
por: Dwitanto, Kuspuji, et al.
Publicado: (2023)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
por: Våtsveen, Thea Kristin, et al.
Publicado: (2016)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Liu, Chao, et al.
Publicado: (2021)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

Receptor-mediated mitophagy regulates EPO production and protects against renal anemia
por: Geng, Guangfeng, et al.
Publicado: (2021)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
por: Zhang, Yaling, et al.
Publicado: (2021)

Author Correction: EPO does not promote interaction between the erythropoietin and beta-common receptors
por: Cheung Tung Shing, Karen S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_he80b966ttdubau56t1mn60u22